MNK up +1.67% percent right now. $MNK High is at 92.67 and

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 1:38 PM

MNK up +1.67% percent right now. $MNK High is at 92.67 and the Low 90.80 with current volume of 302,853.

Recent News posted below.

MNK Mallinckrodt Plc Ordinary Share Recent Headline News

KaloBios (KBIO) Looks Good: Stocks Adds 11.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:25AM CST
KaloBios (KBIO) was a big mover last session, with shares rising over 11% on the day.
MNK: 92.81 (+1.75), IPXL: 28.89 (+0.32), KBIO: 1.94 (+0.14), MYL: 53.97 (+0.86)

Will Evogene (EVGN) Report Wider-than-Expected Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:10PM CST
Evogene (EVGN) is scheduled to report third-quarter 2014 results before the opening bell on Nov 10.
MNK: 92.81 (+1.75), EVGN: 10.30 (-0.20), MON: 116.24 (+1.80), DNDN: 0.23 (-0.71)

Will Inovio (INO) Disappoint Expectations for Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:35PM CST
Inovio (INO), which is scheduled to report third-quarter results on Nov 10, had delivered a negative earnings surprise of 11.76% in the last quarter.
MACK: 8.66 (-0.04), MNK: 92.81 (+1.75), INO: 10.87 (-0.36)

Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:30PM CST
Merrimack Pharmaceuticals, Inc. (MACK) has a Zacks Rank #2 and an Earnings ESP of +437.50%.
MACK: 8.66 (-0.04), MNK: 92.81 (+1.75), BAX: 70.54 (-0.07), LLY: 67.93 (+1.33)

ECB in Action for Stimulus: 3 European Stocks to Buy Now - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 11:14AM CST
ECB is prepared for unconventional policy tools "if needed" to beat ultralow inflation.
MNK: 92.81 (+1.75), SHPG: 200.44 (+1.86), UBS: 17.12 (+0.06)

Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:10PM CST
Agios (AGIO), which is scheduled to report third-quarter results on Nov 7, had delivered a negative earnings surprise of 14.89% in the last quarter.
MNK: 92.81 (+1.75), RNA: 11.87 (-0.27), AGIO: 79.65 (+7.59), CELG: 107.77 (+1.32)

Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:02PM CST
Intercept Pharmaceuticals, Inc (ICPT) is slated to report its third-quarter 2014 results on Nov 7.
MACK: 8.66 (-0.04), MNK: 92.81 (+1.75), DNDN: 0.23 (-0.71), ICPT: 178.84 (+6.25)

Will Isis Pharmaceuticals (ISIS) Disappoint on Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 5:00PM CST
Isis Pharmaceuticals (ISIS) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 7.
MNK: 92.81 (+1.75), BDSI: 16.23 (+0.73), ISIS: 46.26 (+1.67), GSK: 45.19 (+0.28)

Will Synta Pharmaceuticals (SNTA) Post a Wider Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 4:00PM CST
Synta Pharmaceuticals Corp. (SNTA) is scheduled to report third-quarter 2014 results before the opening bell on Nov 6.
MNK: 92.81 (+1.75), SNTA: 3.12 (-0.02), INFI: 13.50 (+0.49), HSP: 56.02 (-0.30)

Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:12PM CST
Repros Therapeutics Inc. (RPRX) has an earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 92.81 (+1.75), PBH: 31.40 (-1.39), RPRX: 9.36 (-0.76), HSP: 56.02 (-0.30)

Is This Trend Making Gilead Sciences, Inc. Worry?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 05, 9:40AM CST
Source: Gilead Sciences via Google Maps If you're sick, you expect your doctor to prescribe the appropriate treatment -- and if that treatment is a revolutionary medicine like Gilead 's Harvoni, you expect that your insurer will pay for it....
MNK: 92.81 (+1.75), VRTX: 116.45 (+0.52), BMRN: 86.94 (+3.03), GILD: 107.33 (+0.88), ALXN: 194.46 (+0.65)

Actavis Beats on Q3 Earnings, Guides Above Expectations - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 9:16AM CST
Actavis' (ACT) third quarter results were boosted by the Forest Labs and Warner Chilcott acquisitions.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), MYL: 53.97 (+0.86), TEVA: 58.09 (+0.39)

Will ARIAD (ARIA) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:00PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) has Earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), ARIA: 6.28 (+0.20), HSP: 56.02 (-0.30)

Will Keryx Biopharmaceuticals (KERX) Post Wider Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:35PM CST
Keryx Biopharmaceuticals, Inc.'s (KERX) is scheduled to report its third-quarter 2014 results on Nov 6.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), HSP: 56.02 (-0.30), KERX: 16.46 (-0.27)

Will Actavis (ACT) Beat Earnings Estimates on Forest Deal? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:20PM CST
Actavis (ACT) is scheduled to report third-quarter 2014 results before the opening bell on Nov 5.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), ALNY: 99.04 (+3.20), HSP: 56.02 (-0.30)

Bristol-Myers Squibb Up on Positive Opdivo Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:46PM CDT
Bristol-Myers Squibb Company announced encouraging data from the phase II CheckMate - 063 study on immuno-oncology drug Opdivo.
MNK: 92.81 (+1.75), AGN: 195.49 (-0.51), ACT: 246.41 (+0.50), BMY: 58.60 (+0.28)

Mylan Beats, Raises Earnings Guidance; Abbott Deal on Track - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:00AM CDT
Mylan (MYL) reported third quarter 2014 earnings of $1.16 per share.
MNK: 92.81 (+1.75), ABT: 43.91 (+0.54), ACT: 246.41 (+0.50), MYL: 53.97 (+0.86)

Pfizer's Trumenba Gains Accelerated Approval in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:04PM CDT
Pfizer Inc.'s (PFE) Trumenba received accelerated FDA approval for prevention of invasive disease caused by Neisseria meningitidis serogroup B in people aged 10 - 25 years.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), PFE: 30.24 (+0.32), MYL: 53.97 (+0.86)

Dr. Reddy's (RDY) Q2 Earnings Fall, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 4:20PM CDT
Dr. Reddy's Laboratories (RDY) reported second-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, down 17% from the year-ago quarter.
MNK: 92.81 (+1.75), ACT: 246.41 (+0.50), MYL: 53.97 (+0.86), RDY: 55.88 (+0.16)

Why Mallinckrodt (MNK) is Poised to Beat Earnings Estimates (Again) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:50AM CDT
Mallinckrodt, a firm in the Medical-Generic & Drug industry space, could again beat earnings, as it has witnessed a nice streak of crushing expectations.
MNK: 92.81 (+1.75)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Why Buyers Are Flocking to Whidbey Island Homes

Something's got folks eyeing Whidbey Island like a gambler with a hot tip—and it ain't just the thrill of a vacation spot. Anyone with half a brain knows real estate moves in waves, and right now, Whidbey Island's caught some serious momentum. You can't ignore the pull of natural beauty, access to city life, and that laid-back vibe that seems to whisper "slow down and...

Patented Foodservice Firm's $1.6M Sale: High ROI Potential

Cooking Up High Margins and Rapid Growth You don’t stumble on opportunities like this every day. A foodservice company out there is posting some mouth-watering numbers, and it’s shaking up the M&A scene. This one’s got patents holding up its brand like a culinary force field, and it’s now on the auction block for a cool $1.6 million. And the numbers? Well, they...

Court Enforces Design Rights: AEKE Blocked in Germany

Court's Verdict: A Lesson in Design Protection Right out the gate, the Cologne Regional Court didn't pull any punches. Speediance got their 'Gym Monster' design yanked from under AEKE over in Germany. Legal swords were drawn after Speediance spotted AEKE's fitness gear looking a bit too familiar at the FIBO trade fair. Somebody should've told AEKE that a tapped shoulder...

PrimeBOT Shines at IFA 2026 with Innovative Awards

A New Chapter in Home Robotics In today's tech-centric world, newcomers often confuse flash with substance. But every now and then, you catch a glimpse of something that might just change how the world spins. At this year's IFA 2026, PrimeBOT didn't just dip its toes into the limelight—it cannonballed right in, drumming up some serious buzz with its PrimeBOT T1 and...

Testing Grounds: Navigating PRN Test Insights

Deciphering the PRN Tester Repetition Today we're staring at what feels like déjà vu—a simple PR test peppered with the classic sentence about a fox and a dog. It's like someone left the 'repeat' function stuck on during a slow day at the office. But hey, let’s dig in. Is there something more behind this repetitive text, or are we grumbling at a wall? Unpacking the...

Softcare Facilitates Standards Delegation Visit to Senegal

Ever seen a whole nation's hygiene industry getting a deep dive from not just one, but three major standards bodies? That's what just went down in Senegal. Softcare opened its doors wide to folks from the Senegalese Association for Standardization (ASN), the International Organization for Standardization (ISO), and the Swedish Institute for Standards (SIS). This was no...

Penetron Strengthens Midwest, Central USA Support Team

Expansion of Penetron's Engineering Support Eyes are on the Midwest and Central USA as Penetron makes a strategic move to bolster their technical support dream team. They've snagged Sean Allison, a heavyweight with more than three decades' worth of grit and know-how from the construction battlefield. Sean, now stationed in the heart of America's Dairyland—Green Bay,...

TECNO's Modular Phone and Mini-PC Win Big at IFA 2026

The Tale of Two Game-Changers TECNO has just scooped up two big-time awards, and I'm here to break it down like no glossy magazine ever could. Picture this: a brand that knows how to keep its foot on the innovation pedal and doesn't shy away from shaking up the tech world. TECNO's got the goods, claiming two prestigious IFA Global Product Technology Innovation Awards this...

TCL Drives Fan Experience at FIBA Women's World Cup

TCL's Slam Dunk on the Global Stage The FIBA Women's Basketball World Cup 2026 in Berlin is set to showcase some incredible talent, and TCL is right in the thick of it. As a FIBA Global Partner, they're spearheading a new wave of fan interactions with their TCLforHer initiative, focusing on tech-enabled fan experiences that go beyond just watching the game. This isn't...

Consumer365 Lauds Happy Head's Custom Hair Treatments

Revolutionizing Hair Loss Treatment The world of hair growth solutions is transforming right before our eyes. Thanks to the folks over at Happy Head and their customizable, dermatologist-prescribed treatments, the days of one-size-fits-all are ending. Consumer365 recently took a dive into Happy Head's model, giving their nod of approval to its personalized approach....